Huntington's disease: from molecular pathogenesis to clinical treatment.
about
Huntingtin is critical both pre- and postsynaptically for long-term learning-related synaptic plasticity in AplysiaTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderEMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington diseaseSumoylation in Synaptic Function and DysfunctionThe P42 peptide and Peptide-based therapies for Huntington's diseaseEpigenetics and Triplet-Repeat Neurological DiseasesThe Unfolded Protein Response and the Role of Protein Disulfide Isomerase in NeurodegenerationInduced pluripotent stem cells for modeling neurological disordersSirt1 and the MitochondriaNeural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challengesAstaxanthin as a Potential Neuroprotective Agent for Neurological DiseasesAn Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington's DiseaseNeurological diseases and painGenetic changes shaping the human brainRAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disordersHuntington's disease: the past, present, and future search for disease modifiers.Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesDeterminants of functional disability in Huntington's disease: role of cognitive and motor dysfunctionMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Synaptic dysfunction and septin protein family members in neurodegenerative diseasesA Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits.Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's diseaseMutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytesN17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic miceLaquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunctionNeuroimmunology of Huntington's Disease: Revisiting Evidence from Human StudiesThe kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's diseaseSex Differences in Circadian Dysfunction in the BACHD Mouse Model of Huntington's DiseaseCompensation in Preclinical Huntington's Disease: Evidence From the Track-On HD StudyEmerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotectionEffectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortScalable production in human cells and biochemical characterization of full-length normal and mutant huntingtinCurrent Status of Huntington's Disease in Korea: A Nationwide Survey and National Registry AnalysisThe long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's diseaseTargeting several CAG expansion diseases by a single antisense oligonucleotideNeuronal Mitophagy in Neurodegenerative DiseasesPotential function for the Huntingtin protein as a scaffold for selective autophagy.N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms.
P2860
Q21131986-86588F81-BFBF-4FB4-A934-DE6F0BAE8DCAQ24626017-65B1DD1C-9924-4107-AE55-DA775463FC75Q24630629-19A5A762-217A-4671-8738-5606FAFE1BEAQ26747536-369DCF3D-85B7-43FE-8F37-87F1CB8329C0Q26764930-9F34BAA7-F45E-4C4F-898F-B8FA62FAC51FQ26770705-2BFC28C7-602D-437B-8451-E17279A04795Q26771343-A9FD3CFB-DFAD-4D37-A4ED-C5D93D9D5E44Q26771402-74A36C82-3B24-4E2F-9A29-4BA1B21FE3F9Q26772894-EB884F8A-7EF4-4029-9C98-D58AC267DDB3Q26775932-CDC16934-F49B-4B66-A3D3-BD5645D51390Q26785969-CD2FCD5B-3D2E-43EC-ABEA-73F653D6BF4AQ26796027-CA7385EC-8C79-4456-806D-B18508E206B7Q26822891-6373BCD2-2797-47AB-B7D2-47663276CDFFQ26822911-A37F4C32-2CFE-4DD2-8B7A-A32BAA91840CQ26823908-B156A023-E31D-4BE6-AEAB-8D7032DDAD09Q26830039-3DDEB697-7B8A-4465-87D0-B59A67D7EAD7Q26830610-8ECB6B5F-0922-4430-9016-62FE62522CA1Q26866192-BB2A952D-5EE1-4BF6-95EA-8012B0C4D5C0Q27005950-154DCB0D-8367-4F62-930E-37A740A7DDF1Q27026829-9B69083F-B7EB-4193-B4EF-C61F6E279ECAQ27301045-C87E9C0B-0F69-4FDC-9BE4-6DC8FCF48E3CQ27301252-92F70F83-8365-4783-9726-BA246D39EA2EQ27305777-F0440080-FD3A-42CA-9349-A0F5A2A87F19Q27306025-2E345F42-2B67-4B35-AADD-78E1199D8643Q27316866-3B5CB471-2DF7-47A1-BB82-94BE84D680C1Q27341821-5701AB27-EA80-4242-82F3-0F08B349A3DAQ28072237-7CEE57DE-EB58-4560-B4EC-CAAB68A8D22DQ28239367-A18894E0-B930-47B6-8CAB-8B4C22EF8F5CQ28386809-69A2B11E-53F2-4513-BF77-37163DE02E91Q28393234-49FC98C3-ABB3-4DD9-8CDE-1943E789DB9CQ28396785-E496D2E5-7B68-4C86-A460-785C6AD14EE9Q28538703-ACF15C31-B672-4564-A361-58464D9A9877Q28544898-040E6808-DA40-4160-8B8E-BA41A0387BE4Q28652090-C1070449-1BB5-4D83-A365-30E595F93AEAQ28705237-B2F22EC4-3AE4-4359-9692-1D7464C92418Q28740870-CBF5C1E5-E235-427C-A6C4-6F3F1B6A266EQ29248361-FB75C21B-82A3-4A95-9D2F-5E5FFBCF3F6EQ30301372-16100813-CF1E-4A11-9FFB-C0AD6E14530DQ30358344-EE1F5050-1C22-4849-9D9A-BB71EA912430Q30441124-9C72B2D1-B61D-4312-85F7-0E81A268E659
P2860
Huntington's disease: from molecular pathogenesis to clinical treatment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Huntington's disease: from molecular pathogenesis to clinical treatment.
@ast
Huntington's disease: from molecular pathogenesis to clinical treatment.
@en
type
label
Huntington's disease: from molecular pathogenesis to clinical treatment.
@ast
Huntington's disease: from molecular pathogenesis to clinical treatment.
@en
prefLabel
Huntington's disease: from molecular pathogenesis to clinical treatment.
@ast
Huntington's disease: from molecular pathogenesis to clinical treatment.
@en
P1433
P1476
Huntington's disease: from molecular pathogenesis to clinical treatment.
@en
P356
10.1016/S1474-4422(10)70245-3
P577
2011-01-01T00:00:00Z